Compare Adaptive Biotechnologies Corp (ADPT) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Eli Lilly And Co — how do they compare? Adaptive Biotechnologies Corp trades at $25.1 (market cap $4.04B), while Eli Lilly And Co trades at $1,220.01 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 267.3× Adaptive Biotechnologies Corp's market cap, and Eli Lilly And Co pays a 0.57% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | LLY | |
|---|---|---|
Market Cap | $4.04B | $1.08T |
Sector | Health | Health |
52-Week High | $25.45 | $1.24K |
52-Week Low | $12.30 | $639.43 |
Enterprise Value | $4.10B | $1.13T |
Dividend Yield | — | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.
Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
